120 related articles for article (PubMed ID: 38598922)
1. Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
Tuninetti V; Virano E; Salutari V; Ricotti A; Pisano C; Ducceschi M; Turitto G; Scandurra G; Petrella MC; Forestieri V; Rizzetto M; Mammoliti S; Artioli G; Cioffi R; Borsotti L; Bellero M; Rognone C; Carbone V; Ferrandina G; Mantiero M; Azzolina C; Geninatti E; Pignata S; Valabrega G
Eur J Cancer; 2024 May; 203():114039. PubMed ID: 38598922
[TBL] [Abstract][Full Text] [Related]
2. Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS; Monk BJ; Vergote I; Miller A; de Melo AC; Kim HS; Kim YM; Lisyanskaya A; Samouëlian V; Lorusso D; Damian F; Chang CL; Gotovkin EA; Takahashi S; Ramone D; Pikiel J; Maćkowiak-Matejczyk B; Guerra Alía EM; Colombo N; Makarova Y; Rischin D; Lheureux S; Hasegawa K; Fujiwara K; Li J; Jamil S; Jankovic V; Chen CI; Seebach F; Weinreich DM; Yancopoulos GD; Lowy I; Mathias M; Fury MG; Oaknin A;
N Engl J Med; 2022 Feb; 386(6):544-555. PubMed ID: 35139273
[TBL] [Abstract][Full Text] [Related]
3. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
[TBL] [Abstract][Full Text] [Related]
4. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Sezer A; Kilickap S; Gümüş M; Bondarenko I; Özgüroğlu M; Gogishvili M; Turk HM; Cicin I; Bentsion D; Gladkov O; Clingan P; Sriuranpong V; Rizvi N; Gao B; Li S; Lee S; McGuire K; Chen CI; Makharadze T; Paydas S; Nechaeva M; Seebach F; Weinreich DM; Yancopoulos GD; Gullo G; Lowy I; Rietschel P
Lancet; 2021 Feb; 397(10274):592-604. PubMed ID: 33581821
[TBL] [Abstract][Full Text] [Related]
5. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
8. Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies.
Kitano S; Shimizu T; Koyama T; Ebata T; Iwasa S; Kondo S; Shimomura A; Fujiwara Y; Yamamoto N; Paccaly A; Li S; Rietschel P; Sims T
Cancer Chemother Pharmacol; 2021 Jan; 87(1):53-64. PubMed ID: 33146741
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
Chung HC; Ros W; Delord JP; Perets R; Italiano A; Shapira-Frommer R; Manzuk L; Piha-Paul SA; Xu L; Zeigenfuss S; Pruitt SK; Leary A
J Clin Oncol; 2019 Jun; 37(17):1470-1478. PubMed ID: 30943124
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.
Moreno V; Garrido P; Papadopoulos KP; De Miguel Luken MJ; Gil-Martin M; Aljumaily R; Rosen LS; Rietschel P; Mohan KK; Yoo SY; Stankevich E; Lowy I; Fury MG
Lung Cancer; 2021 May; 155():151-155. PubMed ID: 33831732
[TBL] [Abstract][Full Text] [Related]
11. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
Minion LE; Tewari KS
Gynecol Oncol; 2018 Mar; 148(3):609-621. PubMed ID: 29666026
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
Gümüş M; Chen CI; Ivanescu C; Kilickap S; Bondarenko I; Özgüroğlu M; Gogishvili M; Turk HM; Cicin I; Harnett J; Mastey V; Naumann U; Reaney M; Konidaris G; Sasane M; Brady KJS; Li S; Gullo G; Rietschel P; Sezer A
Cancer; 2023 Jan; 129(1):118-129. PubMed ID: 36308296
[TBL] [Abstract][Full Text] [Related]
13. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer.
Friedman CF; Snyder Charen A; Zhou Q; Carducci MA; Buckley De Meritens A; Corr BR; Fu S; Hollmann TJ; Iasonos A; Konner JA; Konstantinopoulos PA; Modesitt SC; Sharon E; Aghajanian C; Zamarin D
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004542
[TBL] [Abstract][Full Text] [Related]
15. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
Lan C; Shen J; Wang Y; Li J; Liu Z; He M; Cao X; Ling J; Huang J; Zheng M; Zou G; Yan H; Liu Q; Yang F; Wei W; Deng Y; Xiong Y; Huang X
J Clin Oncol; 2020 Dec; 38(34):4095-4106. PubMed ID: 33052760
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Tamiya M; Tamiya A; Hosoya K; Taniguchi Y; Yokoyama T; Fukuda Y; Hirano K; Matsumoto H; Kominami R; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Kinoshita Y; Hara S; Kumagai T; Fujimoto D
Invest New Drugs; 2019 Dec; 37(6):1266-1273. PubMed ID: 31392549
[TBL] [Abstract][Full Text] [Related]
17. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors.
Lewis KD; Peris K; Sekulic A; Stratigos AJ; Dunn L; Eroglu Z; Chang ALS; Migden MR; Yoo SY; Mohan K; Coates E; Okoye E; Bowler T; Baurain JF; Bechter O; Hauschild A; Butler MO; Hernandez-Aya L; Licitra L; Neves RI; Ruiz ES; Seebach F; Lowy I; Goncalves P; Fury MG
Ann Oncol; 2024 Feb; 35(2):221-228. PubMed ID: 38072158
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
Colombo N; Dubot C; Lorusso D; Caceres MV; Hasegawa K; Shapira-Frommer R; Tewari KS; Salman P; Hoyos Usta E; Yañez E; Gümüş M; Olivera Hurtado de Mendoza M; Samouëlian V; Castonguay V; Arkhipov A; Toker S; Li K; Keefe SM; Monk BJ;
N Engl J Med; 2021 Nov; 385(20):1856-1867. PubMed ID: 34534429
[TBL] [Abstract][Full Text] [Related]
19. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
Rischin D; Gil-Martin M; González-Martin A; Braña I; Hou JY; Cho D; Falchook GS; Formenti S; Jabbour S; Moore K; Naing A; Papadopoulos KP; Baranda J; Fury W; Feng M; Stankevich E; Li J; Yama-Dang NA; Yoo SY; Lowy I; Mathias M; Fury MG
Gynecol Oncol; 2020 Nov; 159(2):322-328. PubMed ID: 32917410
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.
Rischin D; Migden MR; Lim AM; Schmults CD; Khushalani NI; Hughes BGM; Schadendorf D; Dunn LA; Hernandez-Aya L; Chang ALS; Modi B; Hauschild A; Ulrich C; Eigentler T; Stein B; Pavlick AC; Geiger JL; Gutzmer R; Alam M; Okoye E; Mathias M; Jankovic V; Stankevich E; Booth J; Li S; Lowy I; Fury MG; Guminski A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
